About this journal
As of Issue 1/2022 the »European Pharmaceutical Law Review« (EPLR) will be known as the »European Health and Pharma Law Review« (EHPL)
Publication frequency: quarterly
approx. 70 pages
Managing Editor
Jakob Wested, University of Copenhagen
Editorial Board
Ulrich M. Gassner, University of Augsburg
Richard S. Goldberg, Durham University
Leigh Hancher, University of Tilburg / Allen & Overy
Isabelle Huys, KU Leuven
Tomasz Jablonski, European Medicines Agency
Els Janssens, Baker McKenzie
Trudo Lemmens, University of Toronto
Robert Madelin, Foresight International Policy and Regulatory Advisers
Timo Minssen, University of Copenhagen
Marco de Morpurgo, DLA Piper / HEC Paris
Vincenzo Salvatore, University of Insubria/BonelliErede
Florian Schmid, European Comission
European CommissionGeorge Peretz, Monckton Chambers
Claudia Seitz, University of Ghent
Eveline Van Keymeulen, Latham &Watkins LLP
Richard S. Goldberg, Durham University
Leigh Hancher, University of Tilburg / Allen & Overy
Isabelle Huys, KU Leuven
Tomasz Jablonski, European Medicines Agency
Els Janssens, Baker McKenzie
Trudo Lemmens, University of Toronto
Robert Madelin, Foresight International Policy and Regulatory Advisers
Timo Minssen, University of Copenhagen
Marco de Morpurgo, DLA Piper / HEC Paris
Vincenzo Salvatore, University of Insubria/BonelliErede
Florian Schmid, European Comission
European CommissionGeorge Peretz, Monckton Chambers
Claudia Seitz, University of Ghent
Eveline Van Keymeulen, Latham &Watkins LLP
Executive Editor (Lexxion)
Jakob McKernan
Tel.: +49 (0)30 81 45 06-10
mckernan@lexxion.eu